Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Revenue (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Revenue for 5 consecutive years, with $169000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 106.33% year-over-year to $169000.0, compared with a TTM value of $2.2 million through Dec 2025, up 343.7%, and an annual FY2025 reading of $2.2 million, up 554.49% over the prior year.
  • Revenue was $169000.0 for Q4 2025 at Aligos Therapeutics, down from $741000.0 in the prior quarter.
  • Across five years, Revenue topped out at $13.9 million in Q4 2022 and bottomed at -$2.7 million in Q4 2024.
  • Average Revenue over 5 years is $2.1 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Revenue tumbled 169.94% in 2024, then surged 3800.0% in 2025.
  • Year by year, Revenue stood at $367000.0 in 2021, then soared by 3689.37% to $13.9 million in 2022, then crashed by 72.54% to $3.8 million in 2023, then crashed by 169.94% to -$2.7 million in 2024, then soared by 106.33% to $169000.0 in 2025.
  • Business Quant data shows Revenue for ALGS at $169000.0 in Q4 2025, $741000.0 in Q3 2025, and $965000.0 in Q2 2025.